PE20020486A1 - Compuestos triciclicos como inhibidores de la farnesil proteino transferasa - Google Patents

Compuestos triciclicos como inhibidores de la farnesil proteino transferasa

Info

Publication number
PE20020486A1
PE20020486A1 PE2001000865A PE2001000865A PE20020486A1 PE 20020486 A1 PE20020486 A1 PE 20020486A1 PE 2001000865 A PE2001000865 A PE 2001000865A PE 2001000865 A PE2001000865 A PE 2001000865A PE 20020486 A1 PE20020486 A1 PE 20020486A1
Authority
PE
Peru
Prior art keywords
united
compounds
link
farnesil
tricyclic compounds
Prior art date
Application number
PE2001000865A
Other languages
English (en)
Spanish (es)
Inventor
Carmen S Alvarez
Hugh Y Zhu
W Robert Bishop
Alan B Cooper
Jagdish A Desai
Ronald J Doll
Viyyoor Moopil Girijavallabhan
Timothy Guzi
Chia-Yu Huang
Ray A James
Kartik M Keertikar
Ge Li
Keith P Minor
F George Njoroge
Patrick A Pinto
Dinanath F Rane
Bama Santhanam
Bancha Vibulbhan
James J-S Wang
John J Baldwin
Original Assignee
Schering Corp
Pharmacopeia Drug Discovery
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp, Pharmacopeia Drug Discovery filed Critical Schering Corp
Publication of PE20020486A1 publication Critical patent/PE20020486A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PE2001000865A 2000-08-30 2001-08-28 Compuestos triciclicos como inhibidores de la farnesil proteino transferasa PE20020486A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22918300P 2000-08-30 2000-08-30

Publications (1)

Publication Number Publication Date
PE20020486A1 true PE20020486A1 (es) 2002-06-14

Family

ID=22860141

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000865A PE20020486A1 (es) 2000-08-30 2001-08-28 Compuestos triciclicos como inhibidores de la farnesil proteino transferasa

Country Status (27)

Country Link
US (1) US20020198216A1 (OSRAM)
EP (1) EP1313725B1 (OSRAM)
JP (1) JP2004513885A (OSRAM)
KR (1) KR20030034161A (OSRAM)
CN (1) CN100384837C (OSRAM)
AR (1) AR033680A1 (OSRAM)
AT (1) ATE359281T1 (OSRAM)
AU (2) AU8845101A (OSRAM)
BR (1) BR0113675A (OSRAM)
CA (1) CA2420673A1 (OSRAM)
CO (1) CO5640109A2 (OSRAM)
DE (1) DE60127846T2 (OSRAM)
EC (1) ECSP034494A (OSRAM)
ES (1) ES2284686T3 (OSRAM)
HK (1) HK1054548B (OSRAM)
HU (1) HUP0302942A3 (OSRAM)
IL (1) IL154528A0 (OSRAM)
MX (1) MXPA03001849A (OSRAM)
NO (1) NO20030918L (OSRAM)
NZ (1) NZ524246A (OSRAM)
PE (1) PE20020486A1 (OSRAM)
PL (1) PL361103A1 (OSRAM)
RU (1) RU2293734C9 (OSRAM)
SK (1) SK2292003A3 (OSRAM)
TW (1) TWI268280B (OSRAM)
WO (1) WO2002018368A1 (OSRAM)
ZA (1) ZA200301545B (OSRAM)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7342016B2 (en) * 2000-08-30 2008-03-11 Schering Corporation Farnesyl protein transferase inhibitors as antitumor agents
CA2440555A1 (en) 2001-03-14 2002-09-19 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
EP1435959A2 (en) * 2001-10-09 2004-07-14 University of Cincinnati Inhibitors of the egf receptor for the treatment of thyroid cancer
HUP0402401A2 (hu) * 2001-11-30 2005-03-29 Schering Corp. Rák kezelésére szolgáló eljárások egy FPT inhibitor és daganatellenes szerek felhasználásával
EP1453513A1 (en) * 2001-12-03 2004-09-08 Schering Corporation Use of fpt inhibitors and at least two antineoplastic agents in the treatment of cancer
US20030195192A1 (en) * 2002-04-05 2003-10-16 Fortuna Haviv Nicotinamides having antiangiogenic activity
US20040014744A1 (en) * 2002-04-05 2004-01-22 Fortuna Haviv Substituted pyridines having antiangiogenic activity
CA2520172C (en) * 2003-03-27 2012-10-02 Lankenau Institute For Medical Research Novel methods for the treatment of cancer with an indoleamine 2, 3-dioxygenase inhibitor
WO2005000230A2 (en) * 2003-06-05 2005-01-06 Charles Achkar Methods of treating hyperproliferative cell disorders
WO2005001053A2 (en) * 2003-06-09 2005-01-06 Samuel Waksal Method of inhibiting receptor tyrosine kinases with an extracellular antagonist and an intracellular antagonist
ES2235611B2 (es) * 2003-07-25 2006-07-16 Universidade De Santiago De Compostela Metodo cuantitativo para la deteccion de yesotoxinas en productos pesqueros basado en la activacion que producen en las fosfodiesterasas.
ATE417041T1 (de) * 2003-08-07 2008-12-15 Schering Corp Neue farnesylproteintransferaseinhibitoren als antitumormittel
US7592466B2 (en) 2003-10-09 2009-09-22 Abbott Laboratories Ureas having antiangiogenic activity
AU2005319182A1 (en) * 2004-12-21 2006-06-29 Schering Corporation Novel farnesyl protein transferase inhibitors as antitumor agents
RU2361587C1 (ru) * 2008-02-14 2009-07-20 Михаил Владимирович Кутушов Лекарственное средство для лечения онкологических заболеваний
WO2010006432A1 (en) * 2008-07-14 2010-01-21 Queen's University At Kingston Pharmaceutical compositions comprising ret inhibitors and methods for the treatment of cancer
WO2020258211A1 (en) * 2019-06-28 2020-12-30 Anhui Ronghang Biotech Development Co., Ltd. Compositions and methods for treatment of hepatitis b virus infection

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089496A (en) * 1986-10-31 1992-02-18 Schering Corporation Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies
ZA914764B (en) * 1990-06-22 1992-03-25 Schering Corp Bis-benzo or benzopyrido cyclohepta piperidene,piperidylidene and piperazine compounds,compositions and methods of use
US5719148A (en) * 1993-10-15 1998-02-17 Schering Corporation Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
PE92098A1 (es) * 1996-07-31 1998-12-31 Schering Corp N-cianoiminas triciclicas utiles como inhibidores de transferasa de proteina farnesilo
US6071907A (en) * 1996-09-13 2000-06-06 Schering Corporation Tricyclic compounds useful as FPT inhibitors
US5925648A (en) * 1997-07-29 1999-07-20 Schering Corporation Tricyclic N-cyanoimines useful as inhibitors of a farnesyl-protein transferase
ATE293622T1 (de) * 1998-12-18 2005-05-15 Schering Corp Farnesyl protein transferase inhibitoren

Also Published As

Publication number Publication date
AU2001288451C1 (en) 2008-03-06
NO20030918L (no) 2003-04-29
EP1313725B1 (en) 2007-04-11
CO5640109A2 (es) 2006-05-31
HUP0302942A3 (en) 2007-02-28
HK1054548A1 (en) 2003-12-05
MXPA03001849A (es) 2003-06-04
JP2004513885A (ja) 2004-05-13
DE60127846T2 (de) 2008-03-06
DE60127846D1 (en) 2007-05-24
KR20030034161A (ko) 2003-05-01
EP1313725A1 (en) 2003-05-28
RU2293734C9 (ru) 2007-10-10
US20020198216A1 (en) 2002-12-26
AU2001288451B2 (en) 2007-05-24
SK2292003A3 (en) 2003-08-05
BR0113675A (pt) 2003-06-24
IL154528A0 (en) 2003-09-17
AU8845101A (en) 2002-03-13
PL361103A1 (en) 2004-09-20
CN100384837C (zh) 2008-04-30
NO20030918D0 (no) 2003-02-27
CN1471524A (zh) 2004-01-28
ATE359281T1 (de) 2007-05-15
TWI268280B (en) 2006-12-11
ES2284686T3 (es) 2007-11-16
ECSP034494A (es) 2003-04-25
CA2420673A1 (en) 2002-03-07
NZ524246A (en) 2004-11-26
HK1054548B (en) 2007-10-18
RU2293734C2 (ru) 2007-02-20
AR033680A1 (es) 2004-01-07
ZA200301545B (en) 2004-06-22
WO2002018368A1 (en) 2002-03-07
HUP0302942A2 (hu) 2003-12-29

Similar Documents

Publication Publication Date Title
CY1106125T1 (el) Ενωσεις πυρρολινης υποκατεστημενες με ινδαζολυλιο ως αναστολεις κινασης
CY1109479T1 (el) Παραγωγα κιναζολινης
CO5180568A1 (es) Compuestos farmaceuticos, especialmente mutilinas, composiciones farmaceuticas que los contienen
CY1108560T1 (el) Παραγωγα βενζιμιδαζολιου, βενζοθειαζολιου και βενζοξαζολιου και χρηση αυτων ως ρυθμιστες lta4h
DE69914893D1 (de) Glycinamidederivate mit funktionalisierter alkyl- und alkenylseitenkette als inhibitoren der farnesyltransferase
CY1109441T1 (el) Ενδιαμεσα προϊοντα για την παραγωγη διοξανιου-2-αλκυλκαρβαμικου
DE69401658D1 (de) Verwendung von deoxygalactonojirimycin derivaten zu hemmung der glycolipid synthese
BR0112456A (pt) Compostos de piperidina para uso como inibidores de ccr-3
ATE524522T1 (de) Xanthen-farbstoffe
PE20001516A1 (es) Compuestos triciclicos como inhibidores de la farnesil transferasa
CO4900071A1 (es) Derivados de pirido [4´, 3´:4,5] tieno (2,3- d) pirimidina sustituidos en posicion 3
CO4700523A1 (es) Purin-6-onas bisustituidas en 2,9
MX2023006799A (es) Inmunoconjugados anti-cea y usos de estos.
ES2174781T3 (es) Articulo coextruido de resina de policarbonato.
DE60229054D1 (de) Synthese von zyklopentadien derivaten
ATE251145T1 (de) Amino- und hydroxy-substituierte triphenyl-s- triazine als stabilisatoren
DE69910568D1 (de) Furopyridinderivate und ihre therapeutische verwendung
ES2059864T3 (es) Compuesto mesomorfico, composicion de cristal liquido que contiene el mismo y dispositivo de cristal liquido que lo utiliza.
TW200704653A (en) Ultraviolet absorbing polymer for high light resistant recording materials
CY1107287T1 (el) Χρηση της ερυθροποιητινης, καθως και παραγωγων αυτης για τη θεραπεια σχιζοφρενειων και συναφων ψυχωσεων
ES475588A1 (es) Procedimiento para la obtencion de derivados del acido inde-no -2,1-b- tiofen-2-oxamico
PE20030197A1 (es) Derivados de pirrol heteroarilo-substituidos como inhibidores de la produccion de citosinas inflamatorias
CY1105972T1 (el) ΝΕΑ ΥΠΟΚΑΤΕΣΤΗΜΕΝΑ ΠΑΡΑΓΩΓΑ [1,4] ΒΕΝΖΟΔΙΟΞΙΝΟ [2,3-e] ΙΣΟΪΝΔΟΛΙΟΥ, ΜΕΘΟΔΟΣ ΠΑΡΑΣΚΕΥΗΣ ΑΥΤΩΝ ΚΑΙ ΦΑΡΜΑΚΕΥΤΙΚΕΣ ΣΥΝΘΕΣΕΙΣ ΠΟΥ ΤΑ ΠEPΙΕΧΟΥΝ
ES485927A1 (es) Un procedimiento para la produccion de un derivado de feno- xialqueno
TW200517442A (en) Silane compound, polysiloxane and radiation-sensitive resin composition

Legal Events

Date Code Title Description
FC Refusal
FG Grant, registration
FD Application declared void or lapsed